Emilio Werden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emilio Werden has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Amy Brodtmann
Monash University Melbourne Victoria Australia
4 shared publications - Laura J. Bird
Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC Australia
2 shared publications - Mohamed Salah Khlif
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
2 shared publications - Sheila K. Patel
Department of Medicine The University of Melbourne Austin Health, Heidelberg 145 Studley Road, Heidelberg (3084) Victoria Australia
2 shared publications - Adam Southon
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
1 shared publication - Ashley Ian Bush
The University of Melbourne
1 shared publication
Latest Publications
- 31 May 2026
- Published by University of Toronto Press Inc. (UTPress) in Physiotherapy Canada
- Vol. 78 (2) , 259-268
Feasibility of Sarcopenia Assessment and Association With Functional Outcome in Acute Ischemic Stroke
Purpose: The primary aim was to report feasibility of sarcopenia assessment within 7 days of ischemic stroke. Secondary aims were to estimate prevalence of sarcopenia and its association with functional outcome after stroke. Method: Participants, ischemic stroke survivors from two hospital acute stroke units, underwent sarcopenia assessment steps using the revised European Working Group on Sarcopenia in Older People (EWGSOP-2) guidelines within 7 days after stroke. Functional outcome (modified Rankin Scale [mRS]) was assessed 4–6 months post-stroke. Assessment steps were feasible if all participants completed them without serious adverse events. Ordinal regression was used to assess mRS associations at 4–6 months (dependent variable) with grip strength and muscle mass during the acute phase post-stroke (independent variables). Results: All 47 participants completed bioelectrical impedance analyses (BIA) and grip strength with at least the non-stroke affected side without serious adverse events. Six and five participants did not complete chair-rise and gait speed tests, respectively. Four participants (9%) met criteria for sarcopenia. Higher grip strength was independently associated with reduced odds of higher mRS scores. Conclusions: Grip strength and BIA assessments using the EWGSOP-2 guidelines were feasible. Skeletal muscle strength may be an intervention target to improve functional outcome after stroke.
- 31 May 2026
- Published by University of Toronto Press Inc. (UTPress) in Physiotherapy Canada
- Vol. 78 (2) , 259-268
Feasibility of Sarcopenia Assessment and Association With Functional Outcome in Acute Ischemic Stroke
Purpose: The primary aim was to report feasibility of sarcopenia assessment within 7 days of ischemic stroke. Secondary aims were to estimate prevalence of sarcopenia and its association with functional outcome after stroke. Method: Participants, ischemic stroke survivors from two hospital acute stroke units, underwent sarcopenia assessment steps using the revised European Working Group on Sarcopenia in Older People (EWGSOP-2) guidelines within 7 days after stroke. Functional outcome (modified Rankin Scale [mRS]) was assessed 4–6 months post-stroke. Assessment steps were feasible if all participants completed them without serious adverse events. Ordinal regression was used to assess mRS associations at 4–6 months (dependent variable) with grip strength and muscle mass during the acute phase post-stroke (independent variables). Results: All 47 participants completed bioelectrical impedance analyses (BIA) and grip strength with at least the non-stroke affected side without serious adverse events. Six and five participants did not complete chair-rise and gait speed tests, respectively. Four participants (9%) met criteria for sarcopenia. Higher grip strength was independently associated with reduced odds of higher mRS scores. Conclusions: Grip strength and BIA assessments using the EWGSOP-2 guidelines were feasible. Skeletal muscle strength may be an intervention target to improve functional outcome after stroke.
- Open Access
- 11 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1) , 387-396
Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting
Background: Plasma p-tau217 shows exceptional diagnostic performance for Alzheimer's disease (AD) in cohort studies. Recent real-world studies support its validity in more diverse populations. Objective: Test the performance of plasma p-tau217 in representative real-world early-onset cognitive disorders patients. Methods: 118 adult patients with cognitive complaints or potential neurodegenerative diseases (ND) from a single healthcare network in Melbourne, Australia, were categorized into three groups based on clinical diagnosis: non-ND (n = 52), early-onset AD (EOAD, n = 39), and non-AD ND (other-ND, n = 27). Plasma p-tau217 was measured using the Simoa ® ALZpath p-Tau 217 Assay. Results: Plasma p-tau217 was elevated in EOAD (mean ± SD: 1.13 ± 0.51) compared with non-ND (0.31 ± 0.27, p = 5.43e-23) and other-ND (0.23 ± 0.10, p = 9.65e-21). ROC analysis revealed excellent diagnostic performance, with AUCs of 0.944 [95% CI:0.893–0.996] for EOAD versus non-ND and 0.984 [0.962–1.000] for EOAD versus other-ND. Using a binary cut-off (p-tau217 > 0.42 pg/mL), 17% non-ND, 95% EOAD and 7% other-ND were A + . Using a two-tiered cut-off approach (0.40 pg/mL > p-tau217 > 0.63 pg/mL), 4% non-ND, 94% EOAD and 0% other-ND were A + . 10% of participants (n = 12) were within the intermediate range. Using the binary cut-off of p-tau217 > 0.64 pg/mL for T+, 100% EOAD and 0% other-ND A + participants, defined by the two-tiered cut-off approach, were T + . No associations of p-tau217 with age, sex, or ethnicity were found within ND groups. P-tau217 was elevated in individuals with severely impaired renal function. Conclusions: The findings support the clinical utility of plasma p-tau217 in the real-world diagnostic evaluation of EOAD. However, careful interpretation of false positive results in patients with severe renal impairment is required.
- 11 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1) , 387-396
Open AccessReal world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting
Background: Plasma p-tau217 shows exceptional diagnostic performance for Alzheimer's disease (AD) in cohort studies. Recent real-world studies support its validity in more diverse populations. Objective: Test the performance of plasma p-tau217 in representative real-world early-onset cognitive disorders patients. Methods: 118 adult patients with cognitive complaints or potential neurodegenerative diseases (ND) from a single healthcare network in Melbourne, Australia, were categorized into three groups based on clinical diagnosis: non-ND (n = 52), early-onset AD (EOAD, n = 39), and non-AD ND (other-ND, n = 27). Plasma p-tau217 was measured using the Simoa ® ALZpath p-Tau 217 Assay. Results: Plasma p-tau217 was elevated in EOAD (mean ± SD: 1.13 ± 0.51) compared with non-ND (0.31 ± 0.27, p = 5.43e-23) and other-ND (0.23 ± 0.10, p = 9.65e-21). ROC analysis revealed excellent diagnostic performance, with AUCs of 0.944 [95% CI:0.893–0.996] for EOAD versus non-ND and 0.984 [0.962–1.000] for EOAD versus other-ND. Using a binary cut-off (p-tau217 > 0.42 pg/mL), 17% non-ND, 95% EOAD and 7% other-ND were A + . Using a two-tiered cut-off approach (0.40 pg/mL > p-tau217 > 0.63 pg/mL), 4% non-ND, 94% EOAD and 0% other-ND were A + . 10% of participants (n = 12) were within the intermediate range. Using the binary cut-off of p-tau217 > 0.64 pg/mL for T+, 100% EOAD and 0% other-ND A + participants, defined by the two-tiered cut-off approach, were T + . No associations of p-tau217 with age, sex, or ethnicity were found within ND groups. P-tau217 was elevated in individuals with severely impaired renal function. Conclusions: The findings support the clinical utility of plasma p-tau217 in the real-world diagnostic evaluation of EOAD. However, careful interpretation of false positive results in patients with severe renal impairment is required.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Impact of type 2 diabetes mellitus on brain volumes and cognitive performance
Background: Type 2 diabetes (T2DM) is recognised as a major contributor to cognitive decline. People with T2DM demonstrate abnormalities on MRI compared to control individuals. The aim of this analysis was to investigate differences in cognitive performance and brain volume between individuals with T2DM participating in the Diabetes‐and‐Dementia (D2) study and a group of healthy controls (HC) part of the Cognition And Neocortical Volume After Stroke (CANVAS) study.Method: One hundred and fifty individuals with T2DM and 36 cognitively‐normal participants completed neuropsychological assessments and a 3T‐MRI scan. FreeSurfer was used to estimate total brain volume (TBV), mean cortical thickness and subcortical volumes, including the thalami and caudate nuclei. Averages between left and right volumes were calculated for subcortical structures. WMH volumes were estimated manually using FLAIR MRI. Five cognitive domains, including attention, visuospatial skills, memory, language and executive function were computed using z‐scores. These domains were used to compare cognitive performance between individuals with and without T2DM.Demographic and clinical comparisons were completed in MATLAB using Two‐Sample t‐test (age), Fisher Exact test (education, sex, APOE‐e4), and Wilcoxon Rank Sum test (BMI). A linear regression model was used to compare cognitive performance between the two groups with correction for age, sex and education level (more/less than 12 years), as well as total intracranial volume for comparing brain volumes.Result: Participants with T2DM were significantly younger, with a higher BMI, had reduced cortical thickness, significantly smaller TBV and smaller subcortical volumes including thalamic, brainstem, amygdala, accumbens area and choroid plexus. Individuals with T2DM exhibited a poorer cognitive performance on tests of language, memory, attention, and visuospatial skills compared to the HC group. There were no significant differences between the two groups in terms of sex, education level, APOE‐e4 carriage, WMH, hippocampal volume (see Table 1).Conclusion: T2DM is associated with accelerated structural brain aging, manifesting as cerebral atrophy and poorer cognitive function.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessImpact of type 2 diabetes mellitus on brain volumes and cognitive performance
Background: Type 2 diabetes (T2DM) is recognised as a major contributor to cognitive decline. People with T2DM demonstrate abnormalities on MRI compared to control individuals. The aim of this analysis was to investigate differences in cognitive performance and brain volume between individuals with T2DM participating in the Diabetes‐and‐Dementia (D2) study and a group of healthy controls (HC) part of the Cognition And Neocortical Volume After Stroke (CANVAS) study.Method: One hundred and fifty individuals with T2DM and 36 cognitively‐normal participants completed neuropsychological assessments and a 3T‐MRI scan. FreeSurfer was used to estimate total brain volume (TBV), mean cortical thickness and subcortical volumes, including the thalami and caudate nuclei. Averages between left and right volumes were calculated for subcortical structures. WMH volumes were estimated manually using FLAIR MRI. Five cognitive domains, including attention, visuospatial skills, memory, language and executive function were computed using z‐scores. These domains were used to compare cognitive performance between individuals with and without T2DM.Demographic and clinical comparisons were completed in MATLAB using Two‐Sample t‐test (age), Fisher Exact test (education, sex, APOE‐e4), and Wilcoxon Rank Sum test (BMI). A linear regression model was used to compare cognitive performance between the two groups with correction for age, sex and education level (more/less than 12 years), as well as total intracranial volume for comparing brain volumes.Result: Participants with T2DM were significantly younger, with a higher BMI, had reduced cortical thickness, significantly smaller TBV and smaller subcortical volumes including thalamic, brainstem, amygdala, accumbens area and choroid plexus. Individuals with T2DM exhibited a poorer cognitive performance on tests of language, memory, attention, and visuospatial skills compared to the HC group. There were no significant differences between the two groups in terms of sex, education level, APOE‐e4 carriage, WMH, hippocampal volume (see Table 1).Conclusion: T2DM is associated with accelerated structural brain aging, manifesting as cerebral atrophy and poorer cognitive function.
- 27 November 2021
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 56 (1) , 273-281
Atrophy of Ipsilesional Hippocampal Subfields Vary Over First Year After Ischemic Stroke
Background: The structural integrity of hippocampal subfields has been investigated in many neurological disorders and was shown to be better associated with cognitive performance than whole hippocampus. In stroke, hippocampal atrophy is linked to cognitive impairment, but it is unknown whether the hippocampal subfields atrophy differently.Purpose: To evaluate longitudinal hippocampal subfield atrophy in first year poststroke, in comparison with atrophy in healthy individuals.Study Type: Cohort.Subjects: A total of 92 ischemic stroke (age: 67 ± 12 years, 63 men) and 39 healthy participants (age: 69 ± 7 years, 24 men).Field Strength/Sequence: A3 T/T1‐MPRAGE, T2‐SPACE, and T2‐FLAIR.Assessment: FreeSurfer (6.0) was used to delineate 12 hippocampal subfields. Whole hippocampal volume was computed as sum of subfield volumes excluding hippocampal fissure volume. Separate assessments were completed for contralesional and ipsilesional hippocampi.Statistical Tests: A mixed‐effect regression model was used to compare subfield volumes cross‐sectionally between healthy and stroke groups and longitudinally between 3‐month and 12‐month timepoints. False discovery rate at 0.05 significance level was used to correct for multiple comparisons. Also, a receiver operating characteristic (ROC) curve analysis was performed to assess differentiation between healthy and stroke participants based on subfield volumes.Results: There were no volume differences between groups at 3 months, but there was a significant difference (P = 0.027) in whole hippocampal volume reduction over time between control and stroke ipsilesionally. Thus, the ipsilesional whole hippocampal volume in stroke became significantly smaller (P = 0.035) at 12 months. The hippocampal tail was the highest single‐region contributor (22.7%) to ipsilesional hippocampal atrophy (1.19%) over 9 months. The cornu ammonis areas (CA1) subfield volume reduction was minimal in controls and stroke contralesionally but significant ipsilesionally (P = 0.007). CA1 volume significantly outperformed whole hippocampal volume (P < 0.01) in discriminating between stroke participants and healthy controls in ROC curve analysis.Data Conclusion: Greater stroke‐induced effects were observed in the ipsilesional hippocampus anteriorly in CA1 and posteriorly in the hippocampal tail. Atrophy of CA1 and hippocampal tail may provide a better link to cognitive impairment than whole hippocampal atrophy.Level of Evidence: 2Technical Efficacy Stage: 3
- 27 November 2021
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 56 (1) , 273-281
Atrophy of Ipsilesional Hippocampal Subfields Vary Over First Year After Ischemic Stroke
Background: The structural integrity of hippocampal subfields has been investigated in many neurological disorders and was shown to be better associated with cognitive performance than whole hippocampus. In stroke, hippocampal atrophy is linked to cognitive impairment, but it is unknown whether the hippocampal subfields atrophy differently.Purpose: To evaluate longitudinal hippocampal subfield atrophy in first year poststroke, in comparison with atrophy in healthy individuals.Study Type: Cohort.Subjects: A total of 92 ischemic stroke (age: 67 ± 12 years, 63 men) and 39 healthy participants (age: 69 ± 7 years, 24 men).Field Strength/Sequence: A3 T/T1‐MPRAGE, T2‐SPACE, and T2‐FLAIR.Assessment: FreeSurfer (6.0) was used to delineate 12 hippocampal subfields. Whole hippocampal volume was computed as sum of subfield volumes excluding hippocampal fissure volume. Separate assessments were completed for contralesional and ipsilesional hippocampi.Statistical Tests: A mixed‐effect regression model was used to compare subfield volumes cross‐sectionally between healthy and stroke groups and longitudinally between 3‐month and 12‐month timepoints. False discovery rate at 0.05 significance level was used to correct for multiple comparisons. Also, a receiver operating characteristic (ROC) curve analysis was performed to assess differentiation between healthy and stroke participants based on subfield volumes.Results: There were no volume differences between groups at 3 months, but there was a significant difference (P = 0.027) in whole hippocampal volume reduction over time between control and stroke ipsilesionally. Thus, the ipsilesional whole hippocampal volume in stroke became significantly smaller (P = 0.035) at 12 months. The hippocampal tail was the highest single‐region contributor (22.7%) to ipsilesional hippocampal atrophy (1.19%) over 9 months. The cornu ammonis areas (CA1) subfield volume reduction was minimal in controls and stroke contralesionally but significant ipsilesionally (P = 0.007). CA1 volume significantly outperformed whole hippocampal volume (P < 0.01) in discriminating between stroke participants and healthy controls in ROC curve analysis.Data Conclusion: Greater stroke‐induced effects were observed in the ipsilesional hippocampus anteriorly in CA1 and posteriorly in the hippocampal tail. Atrophy of CA1 and hippocampal tail may provide a better link to cognitive impairment than whole hippocampal atrophy.Level of Evidence: 2Technical Efficacy Stage: 3